These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 33690135)

  • 41. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
    Collings SL; Lefèvre C; Johnson ME; Evans D; Hack G; Stynes G; Maguire A
    PLoS One; 2017; 12(10):e0185642. PubMed ID: 29016695
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study.
    Staerk L; Gerds TA; Lip GYH; Ozenne B; Bonde AN; Lamberts M; Fosbøl EL; Torp-Pedersen C; Gislason GH; Olesen JB
    J Intern Med; 2018 Jan; 283(1):45-55. PubMed ID: 28861925
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review.
    Briere JB; Bowrin K; Coleman C; Fauchier L; Levy P; Folkerts K; Toumi M; Taieb V; Millier A; Wu O
    Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):27-36. PubMed ID: 30169975
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care.
    Vinogradova Y; Coupland C; Hill T; Hippisley-Cox J
    BMJ; 2018 Jul; 362():k2505. PubMed ID: 29973392
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States.
    Baker CL; Dhamane AD; Mardekian J; Dina O; Russ C; Rosenblatt L; Lingohr-Smith M; Menges B; Lin J; Nadkarni A
    Adv Ther; 2019 Jan; 36(1):162-174. PubMed ID: 30499067
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study.
    Paciaroni M; Agnelli G; Falocci N; Tsivgoulis G; Vadikolias K; Liantinioti C; Chondrogianni M; Bovi P; Carletti M; Cappellari M; Zedde M; Ntaios G; Karagkiozi E; Athanasakis G; Makaritsis K; Silvestrelli G; Lanari A; Ciccone A; Putaala J; Tomppo L; Tatlisumak T; Abdul-Rahim AH; Lees KR; Alberti A; Venti M; Acciarresi M; D'Amore C; Becattini C; Mosconi MG; Cimini LA; Soloperto R; Masotti L; Vannucchi V; Lorenzini G; Tassi R; Guideri F; Acampa M; Martini G; Sohn SI; Marcheselli S; Mumoli N; De Lodovici ML; Bono G; Furie KL; Tadi P; Yaghi S; Toni D; Letteri F; Tassinari T; Kargiotis O; Lotti EM; Flomin Y; Mancuso M; Maccarrone M; Giannini N; Bandini F; Pezzini A; Poli L; Padovani A; Scoditti U; Denti L; Consoli D; Galati F; Sacco S; Carolei A; Tiseo C; Gourbali V; Orlandi G; Giuntini M; Chiti A; Giorli E; Gialdini G; Corea F; Ageno W; Bellesini M; Colombo G; Monaco S; Maimone Baronello M; Karapanayiotides T; Caso V
    J Am Heart Assoc; 2017 Nov; 6(12):. PubMed ID: 29220330
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis.
    Sakuma I; Uchiyama S; Atarashi H; Inoue H; Kitazono T; Yamashita T; Shimizu W; Ikeda T; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Shimokawa H
    Heart Vessels; 2019 Nov; 34(11):1839-1851. PubMed ID: 31127325
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Direct oral anticoagulants in the prevention of stroke in breast cancer patients with atrial fibrillation during adjuvant endocrine therapy: A cohort study.
    Pacholczak-Madej R; Bazan-Socha S; Zaręba L; Undas A; Dropiński J
    Int J Cardiol; 2021 Feb; 324():78-83. PubMed ID: 32931852
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
    Skjøth F; Larsen TB; Rasmussen LH; Lip GY
    Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation.
    Kido K; Ngorsuraches S
    Ann Pharmacother; 2019 Feb; 53(2):165-170. PubMed ID: 30130979
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
    Sato T; Aizawa Y; Fuse K; Fujita S; Ikeda Y; Kitazawa H; Takahashi M; Okabe M
    J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):3280-3288. PubMed ID: 30121155
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland.
    Mueller T; Alvarez-Madrazo S; Robertson C; Wu O; Bennie M
    Br J Clin Pharmacol; 2019 Feb; 85(2):422-431. PubMed ID: 30423191
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure.
    Amin A; Garcia Reeves AB; Li X; Dhamane A; Luo X; Di Fusco M; Nadkarni A; Friend K; Rosenblatt L; Mardekian J; Pan X; Yuce H; Keshishian A
    PLoS One; 2019; 14(3):e0213614. PubMed ID: 30908512
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation.
    Okishige K; Nakamura T; Aoyagi H; Kawaguchi N; Yamashita M; Kurabayashi M; Suzuki H; Asano M; Shimura T; Yamauchi Y; Sasano T; Hirao K
    J Cardiol; 2017 Jan; 69(1):11-15. PubMed ID: 27160710
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 57. [Pharmaco-utilization and outcomes in patients treated with oral anticoagulants from 2014 to 2015: evidences from administrative databases of the Romagna Local Health Unit].
    Degli Esposti L; Perrone V; Saragoni S; Buda S; Piovaccari G
    G Ital Cardiol (Rome); 2020 Jan; 21(1):25-33. PubMed ID: 31960832
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
    Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
    Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies.
    Deitelzweig S; Farmer C; Luo X; Vo L; Li X; Hamilton M; Horblyuk R; Ashaye A
    Curr Med Res Opin; 2017 Sep; 33(9):1583-1594. PubMed ID: 28644048
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness and safety among direct oral anticoagulants in nonvalvular atrial fibrillation: A multi-database cohort study with meta-analysis.
    Durand M; Schnitzer ME; Pang M; Carney G; Eltonsy S; Filion KB; Fisher A; Jun M; Kuo IF; Matteau A; Paterson JM; Quail J; Renoux C;
    Br J Clin Pharmacol; 2021 Jun; 87(6):2589-2601. PubMed ID: 33242339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.